Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Kenya.
Antibodies
Healthcare Workers
SARS-CoV-2
Seroprevalence
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
29 01 2022
29 01 2022
Historique:
received:
15
03
2021
pubmed:
25
4
2021
medline:
3
2
2022
entrez:
24
4
2021
Statut:
ppublish
Résumé
Few studies have assessed the seroprevalence of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among healthcare workers (HCWs) in Africa. We report findings from a survey among HCWs in 3 counties in Kenya. We recruited 684 HCWs from Kilifi (rural), Busia (rural), and Nairobi (urban) counties. The serosurvey was conducted between 30 July and 4 December 2020. We tested for immunoglobulin G antibodies to SARS-CoV-2 spike protein, using enzyme-linked immunosorbent assay. Assay sensitivity and specificity were 92.7 (95% CI, 87.9-96.1) and 99.0% (95% CI, 98.1-99.5), respectively. We adjusted prevalence estimates, using bayesian modeling to account for assay performance. The crude overall seroprevalence was 19.7% (135 of 684). After adjustment for assay performance, seroprevalence was 20.8% (95% credible interval, 17.5%-24.4%). Seroprevalence varied significantly (P < .001) by site: 43.8% (95% credible interval, 35.8%-52.2%) in Nairobi, 12.6% (8.8%-17.1%) in Busia and 11.5% (7.2%-17.6%) in Kilifi. In a multivariable model controlling for age, sex, and site, professional cadre was not associated with differences in seroprevalence. These initial data demonstrate a high seroprevalence of antibodies to SARS-CoV-2 among HCWs in Kenya. There was significant variation in seroprevalence by region, but not by cadre.
Sections du résumé
BACKGROUND
Few studies have assessed the seroprevalence of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among healthcare workers (HCWs) in Africa. We report findings from a survey among HCWs in 3 counties in Kenya.
METHODS
We recruited 684 HCWs from Kilifi (rural), Busia (rural), and Nairobi (urban) counties. The serosurvey was conducted between 30 July and 4 December 2020. We tested for immunoglobulin G antibodies to SARS-CoV-2 spike protein, using enzyme-linked immunosorbent assay. Assay sensitivity and specificity were 92.7 (95% CI, 87.9-96.1) and 99.0% (95% CI, 98.1-99.5), respectively. We adjusted prevalence estimates, using bayesian modeling to account for assay performance.
RESULTS
The crude overall seroprevalence was 19.7% (135 of 684). After adjustment for assay performance, seroprevalence was 20.8% (95% credible interval, 17.5%-24.4%). Seroprevalence varied significantly (P < .001) by site: 43.8% (95% credible interval, 35.8%-52.2%) in Nairobi, 12.6% (8.8%-17.1%) in Busia and 11.5% (7.2%-17.6%) in Kilifi. In a multivariable model controlling for age, sex, and site, professional cadre was not associated with differences in seroprevalence.
CONCLUSION
These initial data demonstrate a high seroprevalence of antibodies to SARS-CoV-2 among HCWs in Kenya. There was significant variation in seroprevalence by region, but not by cadre.
Identifiants
pubmed: 33893491
pii: 6248493
doi: 10.1093/cid/ciab346
pmc: PMC8135298
mid: EMS123289
doi:
Substances chimiques
Antibodies, Viral
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
288-293Subventions
Organisme : Wellcome Trust
ID : MR/R006083/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 220991/Z/20/Z
Pays : United Kingdom
Organisme : Bill & Melinda Gates Foundation
ID : INV-017547
Pays : United States
Organisme : Medical Research Council
ID : MR/S005293/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 203077
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R010161/1
Pays : United Kingdom
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Nat Commun. 2020 Jul 8;11(1):3500
pubmed: 32641730
N Engl J Med. 2020 Oct 29;383(18):1782-1784
pubmed: 32871061
Thorax. 2020 Dec;75(12):1089-1094
pubmed: 32917840
JAMA. 2020 Sep 1;324(9):893-895
pubmed: 32780804
N Engl J Med. 2021 Feb 11;384(6):533-540
pubmed: 33369366
Science. 2021 Jan 1;371(6524):79-82
pubmed: 33177105
Lancet. 2020 May 23;395(10237):1608-1610
pubmed: 32401714
Nat Commun. 2021 Jun 25;12(1):3966
pubmed: 34172732
Lancet. 2020 May 2;395(10234):1405-1406
pubmed: 32243778
J Hosp Infect. 2021 Feb;108:120-134
pubmed: 33212126
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Am J Trop Med Hyg. 2021 Feb 16;104(4):1526-1530
pubmed: 33591936
Lancet Glob Health. 2021 Mar;9(3):e257-e266
pubmed: 33515512
J Infect Dis. 2020 Nov 9;222(11):1772-1775
pubmed: 32856712
Am J Trop Med Hyg. 2021 Jan;104(1):91-94
pubmed: 33185181
Ann Intern Med. 2020 Jul 21;173(2):120-136
pubmed: 32369541